A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 111 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2004, is one of 22 in phase 3, and was the 5th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 777 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 4th largest by enrollment, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 6th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg by subcutaneous injection every other week or every week
Also known as: ABT-D2E7, Humira
Percentage of Subjects Achieving Clinical Remission
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Percentage of Subjects Achieving Clinical Remission
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 48
Percentage of Subjects Achieving Clinical Remission
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 108
Percentage of Subjects Achieving Clinical Remission
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 204
Percentage of Subjects Achieving Clinical Response 100 (CR-100)
A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Percentage of Subjects Achieving Clinical Response 70 (CR-70)
A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Percentage of Subjects Achieving Steroid-free Clinical Remission
Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of \<150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Percentage of Subjects Achieving Steroid-free CR-100
Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Percentage of Subjects With Fistula Remission
Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.
Time frame: Week 156
Percentage of Subjects With Infection
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Serious Infection
Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Malignancy
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Lymphoma
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Nonmelanoma Skin Cancer
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Injection Site Reaction-related Adverse Event
An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Congestive Heart Failure
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Demyelinating Disease
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Hepatic-related Adverse Event
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Allergic Reaction-related Adverse Event
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Lupus-like Syndrome
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Hematologic-related Adverse Event
Time frame: Up to 262 weeks of adalimumab treatment
Percentage of Subjects With Fatal Adverse Event
Time frame: Up to 262 weeks of adalimumab treatment
| Milestone | Open-label Adalimumab |
|---|---|
| Started | 777 |
| Completed | 400 |
| Not completed | 377 |
| Withdrew: Adverse event | 122 |
| Withdrew: Withdrawal by subject | 58 |
| Withdrew: Lost to follow-up | 27 |
| Withdrew: Protocol violation | 13 |
| Withdrew: Lack of efficacy | 93 |
| Withdrew: Pregnancy | 14 |
| Withdrew: Investigative site closure | 8 |
| Withdrew: Subject moved/relocated | 7 |
| Withdrew: Subject non-compliance | 6 |
| Withdrew: Subject started commercial humira | 5 |
| Withdrew: Subject choice | 3 |
| Withdrew: Loss of response/no improvement | 3 |
| Withdrew: Sponsor stopped study | 1 |
| Withdrew: Administrative reasons | 2 |
| Withdrew: Investigator's decision | 2 |
| Withdrew: Subject wants to get pregnant | 4 |
| Withdrew: Use of prohibited medication | 2 |
| Withdrew: Planned surgery | 2 |
| Withdrew: Increased infection rate | 1 |
| Withdrew: Ineligible | 1 |
| Withdrew: Colonic stricture | 1 |
| Withdrew: Sponsor discontinued trial | 1 |
| Withdrew: Sponsor discretion - trial ended early | 1 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Remission | 59.4 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Remission | 68.8 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Remission | 69.5 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Remission | 46.7 |
A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Response 100 (CR-100) | 85.7 |
A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Clinical Response 70 (CR-70) | 91.2 |
Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of \<150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Steroid-free Clinical Remission | 63.1 |
Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects Achieving Steroid-free CR-100 | 74.8 |
Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Fistula Remission | 55.8 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Infection | 80.2 |
Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Serious Infection | 10.6 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Malignancy | 4.1 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Lymphoma | 0.1 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Nonmelanoma Skin Cancer | 1.8 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma) | 2.3 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer) | 2.4 |
An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Injection Site Reaction-related Adverse Event | 22.8 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis) | 4.9 |
| Percentage of subjects | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Congestive Heart Failure | 0 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Demyelinating Disease | 0.3 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Hepatic-related Adverse Event | 8.1 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Allergic Reaction-related Adverse Event | 2.7 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Lupus-like Syndrome | 0.4 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Hematologic-related Adverse Event | 1.5 |
| Percentage of participants | Open-label Adalimumab |
|---|---|
| Percentage of Subjects With Fatal Adverse Event | 0.3 |
Collected over Up to 262 weeks of adalimumab treatment (includes adalimumab treatment in previous study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Adalimumab | — | 296/777 (38.1%) | 720/777 (92.7%) |
| Event | Open-label Adalimumab |
|---|---|
| Crohn's diseaseGastrointestinal disorders | 92/777 |
| Small intestinal obstructionGastrointestinal disorders | 30/777 |
| Anal abscessInfections and infestations | 15/777 |
| Abdominal painGastrointestinal disorders | 11/777 |
| Intestinal obstructionGastrointestinal disorders | 10/777 |
| Anal fistulaGastrointestinal disorders | 8/777 |
| PneumoniaInfections and infestations | 8/777 |
| DehydrationMetabolism and nutrition disorders | 7/777 |
| NauseaGastrointestinal disorders | 6/777 |
| NephrolithiasisRenal and urinary disorders | 6/777 |
| Event | Open-label Adalimumab |
|---|---|
| Crohn's diseaseGastrointestinal disorders | 309/777 |
| NasopharyngitisInfections and infestations | 203/777 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 192/777 |
| Abdominal painGastrointestinal disorders | 180/777 |
| Upper respiratory tract infectionInfections and infestations | 150/777 |
| NauseaGastrointestinal disorders | 142/777 |
| HeadacheNervous system disorders | 141/777 |
| InfluenzaInfections and infestations | 137/777 |
| DiarrhoeaGastrointestinal disorders | 118/777 |
| SinusitisInfections and infestations | 116/777 |
| Age Continuous(years) | Open-label Adalimumab |
|---|---|
| Mean | 38.0 ± 11.75 |
| Sex: Female, Male(Participants) | Open-label Adalimumab |
|---|---|
| Female | 485 |
| Male | 292 |
| Region of Enrollment(participants) | Open-label Adalimumab |
|---|---|
| United States | 349 |
| Australia | 40 |
| Belgium | 66 |
| Canada | 197 |
| Denmark | 18 |
| France | 24 |
| Germany | 5 |
| Hungary | 8 |
| Italy | 9 |
| Netherlands | 10 |
| Poland | 12 |
| South Africa | 20 |
| Spain | 3 |
| Sweden | 5 |
| United Kingdom | 11 |
Showing the first 100 of 111 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2004, a primary completion of Mar 2006 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab